---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-066456"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:03:34.767560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics reports Q2 2023 results; IPO nets $20.5M, INT230-6 shows survival benefit in sarcoma

## Summary
- Closed upsized IPO of 3.9M shares at $5.00/sh, net proceeds $20.5M; cash runway extended into early Q3 2025.
- INT230-6 data at ASCO: median OS 21.3 months in refractory metastatic sarcoma vs historical 7-10 months.
- Net operating loss $1.2M in Q2 2023 vs $1.9M in Q2 2022; non-operating loss $2.3M from convertible debt discount included.
- Plan to file IND for phase 3 study of INT230-6 in soft tissue sarcoma by end of 2023.
- Additional INVINCIBLE breast cancer data expected by year-end; phase 2/3 program planned.

## SEC filing metadata
- accession: 0001213900-23-066456
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000121390023066456/0001213900-23-066456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000121390023066456/ea183398-8k_intensity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-066456
- JSON: https://secwatch.observer/filing/0001213900-23-066456.json
- Plain text: https://secwatch.observer/filing/0001213900-23-066456.txt

## Key facts
- Earnings Releases
  INTENSITY THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income Net Operating Loss for the second quarter ended June 30, 2023 was $1.2 million.
  - Period: second quarter ended June 30, 2023
  - Net income: Net Operating Loss for the second quarter ended June 30, 2023 was $1.2 million
  - Result: reported results
  source text: Intensity Therapeutics, Inc. (the “ Company ”) released its financial results for the quarter ended June 30, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000121390023066456/0001213900-23-066456-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.